SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 223 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q1 2021. The put-call ratio across all filers is 0.22 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $285,598 | +26.1% | 10,359 | +65.7% | 0.00% | 0.0% |
| Q1 2023 | $226,438 | +5.1% | 6,250 | +3.5% | 0.00% | 0.0% |
| Q4 2022 | $215,483 | +7.7% | 6,041 | +2.1% | 0.00% | 0.0% |
| Q3 2022 | $200,000 | +115.1% | 5,914 | +84.6% | 0.00% | 0.0% |
| Q2 2022 | $93,000 | -3.1% | 3,204 | +7.4% | 0.00% | 0.0% |
| Q1 2022 | $96,000 | +190.9% | 2,983 | +163.3% | 0.00% | – |
| Q4 2021 | $33,000 | +17.9% | 1,133 | +8.7% | 0.00% | – |
| Q3 2021 | $28,000 | 0.0% | 1,042 | +16.3% | 0.00% | – |
| Q2 2021 | $28,000 | +16.7% | 896 | -2.2% | 0.00% | – |
| Q1 2021 | $24,000 | +242.9% | 916 | +233.1% | 0.00% | – |
| Q4 2020 | $7,000 | +40.0% | 275 | +22.2% | 0.00% | – |
| Q3 2020 | $5,000 | +25.0% | 225 | +28.6% | 0.00% | – |
| Q2 2020 | $4,000 | 0.0% | 175 | +34.6% | 0.00% | – |
| Q3 2019 | $4,000 | 0.0% | 130 | 0.0% | 0.00% | – |
| Q2 2019 | $4,000 | +300.0% | 130 | +766.7% | 0.00% | – |
| Q2 2018 | $1,000 | – | 15 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 426,500 | $11,754,340 | 3.96% |
| ASHFORD CAPITAL MANAGEMENT INC | 916,747 | $25,274,715 | 3.72% |
| ARMISTICE CAPITAL, LLC | 5,092,000 | $140,386,440 | 2.15% |
| S&T BANK/PA | 215,578 | $5,943 | 1.15% |
| Aristotle Capital Boston, LLC | 1,187,981 | $32,752,634 | 1.06% |
| RICE HALL JAMES & ASSOCIATES, LLC | 544,468 | $15,010,983 | 0.95% |
| Tributary Capital Management, LLC | 352,429 | $9,716,468 | 0.92% |
| Bridge City Capital, LLC | 65,297 | $1,800,238 | 0.91% |
| Integral Health Asset Management, LLC | 220,000 | $6,065,400 | 0.84% |
| Retirement Planning Co of New England, Inc. | 51,608 | $1,422,833 | 0.79% |